Pros | ![]() Among most bought funds within the category. ![]() Larger AUM within category. ![]() Beats FD returns for both 3Y & 5Y duration. | ![]() Beats FD returns for both 3Y & 5Y duration. | ||
Cons | - | ![]() 5Y returns in the bottom 25% of the category. ![]() 3Y returns in the bottom 25% of the category. |
INDMoney rank | 7/8 | 8/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 12 Years | 5 Years | ||
Fund Size | 8081 Cr | 815 Cr | ||
Min Investment | SIP ₹100 Lumpsum ₹5000 | SIP ₹100 Lumpsum ₹1000 | ||
Expense Ratio | 0.91% | 1.06% | ||
Exit Load | 1% | 1% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 40 | 30 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (13.43%) Divi's Laboratories Ltd (9.28%) Lupin Ltd (7.27%) Cipla Ltd (5.71%) Apollo Hospitals Enterprise Ltd (5.31%) | Sun Pharmaceuticals Industries Ltd (14.61%) Cipla Ltd (8.44%) Torrent Pharmaceuticals Ltd (7.05%) Apollo Hospitals Enterprise Ltd (6.9%) Abbott India Ltd (6.14%) | ||
No of Sectors | 1 | 2 | ||
Top 3 Sectors | Health (100%) | Health (99.24%) Basic Materials (0.76%) | ||
Equity % | 99.46% | 98.79% | ||
Debt % | - | - | ||
P/E | 35.57 | 35.29 | ||
P/B | 5.87 | 5.9 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 3.89% | 2.58% | ||
3-Month Return | 7.52% | 5.1% | ||
6-Month Return | -1.67% | -3.31% | ||
1-Year Return | 17.52% | 16.25% | ||
3-Year Return | 21.24% | 20.24% | ||
5-Year Return | 23.82% | 21.38% |
Sharpe | 0.81 | 0.74 | ||
Alpha | 0.5 | -0.56 | ||
Beta | 0.9 | 0.96 | ||
Standard Deviation | 15.85 | 16.88 | ||
Information Ratio | -0.21 | -0.34 |
Description | Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund.The fund could potentially beat inflation in the long-run. | Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Sailesh Raj Bhan,Kinjal Desai | Dhaval Shah |